C79.00: Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.00, secondary malignant neoplasm of unspecified kidney and renal pelvis, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 29 HCPCS Level II codes, including Q2043 (Sipuleucel-t, minimum of 50 million autologous cd54+ cells…), G0340 (Image-guided robotic linear accelerator-based stereotactic…), G0339 (Image-guided robotic linear accelerator-based stereotactic…). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with C79.00 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Special coverage instructions apply | — | 1 |
| G0340 | Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment | Carrier judgment | — | 1 |
| G0339 | Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatment | Carrier judgment | — | 1 |
| G0563 | Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractions | Carrier judgment | — | 1 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Special coverage instructions apply | — | 1 |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Carrier judgment | — | 1 |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Special coverage instructions apply | — | 1 |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Special coverage instructions apply | — | 1 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Carrier judgment | — | 1 |
| J1447 | Injection, tbo-filgrastim, 1 microgram | Special coverage instructions apply | — | 1 |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5127 | Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg | Special coverage instructions apply | — | 1 |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| Q5148 | Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram | Special coverage instructions apply | — | 1 |
| Q5169 | Injection, pegfilgrastim-unne (armlupeg), biosimilar, 0.5 mg | Carrier judgment | — | 1 |
| E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $9,917.33–$11,667.45 (NU) | 1 |
| E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) | Special coverage instructions apply | $10,969.75–$11,380.88 (NU) | 1 |
| E0782 | Infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $5,200.92–$6,118.73 (NU) | 1 |
| E0785 | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement | Special coverage instructions apply | $572.38–$673.39 (KF) | 1 |
| J7999 | Compounded drug, not otherwise classified | Special coverage instructions apply | — | 1 |
4 more codes are listed. See every code with payment by region in Caduvo.
Medicare policy articles listing C79.00
- A55719: Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 1 Level II codes)
- A56874: Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) (Wellpoint Federal (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L35076
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B); 16 Level II codes). LCD with the same title: L37176
- A56695: Billing and Coding: Implantable Infusion Pump (Palmetto GBA (MAC - Part B); 9 Level II codes). LCD with the same title: L33461
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other C79 diagnoses (Secondary malignant neoplasm of other and unspecified sites)
- C79.01 — Secondary malignant neoplasm of right kidney and renal pelvis
- C79.02 — Secondary malignant neoplasm of left kidney and renal pelvis
- C79.10 — Secondary malignant neoplasm of unspecified urinary organs
- C79.11 — Secondary malignant neoplasm of bladder
- C79.19 — Secondary malignant neoplasm of other urinary organs
- C79.2 — Secondary malignant neoplasm of skin
- C79.31 — Secondary malignant neoplasm of brain
- C79.32 — Secondary malignant neoplasm of cerebral meninges
- C79.40 — Secondary malignant neoplasm of unspecified part of nervous system
- C79.49 — Secondary malignant neoplasm of other parts of nervous system
- C79.51 — Secondary malignant neoplasm of bone
- C79.52 — Secondary malignant neoplasm of bone marrow
- C79.61 — Secondary malignant neoplasm of right ovary
- C79.62 — Secondary malignant neoplasm of left ovary
- C79.63 — Secondary malignant neoplasm of bilateral ovaries
- C79.70 — Secondary malignant neoplasm of unspecified adrenal gland
- C79.71 — Secondary malignant neoplasm of right adrenal gland
- C79.72 — Secondary malignant neoplasm of left adrenal gland
- C79.81 — Secondary malignant neoplasm of breast
- C79.82 — Secondary malignant neoplasm of genital organs
- C79.89 — Secondary malignant neoplasm of other specified sites
- C79.9 — Secondary malignant neoplasm of unspecified site
Frequently asked questions
Does Medicare cover C79.00 (Secondary malignant neoplasm of unspecified kidney and…)?
Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list C79.00 as a covered diagnosis for 29 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 C79.00?
The Level II codes from the policies most specific to this diagnosis are Q2043 (Sipuleucel-t, minimum of 50 million autologous cd54+ cells…, 1 article); G0340 (Image-guided robotic linear accelerator-based stereotactic…, 1 article); G0339 (Image-guided robotic linear accelerator-based stereotactic…, 1 article); G0563 (Stereotactic body radiation therapy, treatment delivery…, 1 article); Q5110 (Injection, filgrastim-aafi, biosimilar, (nivestym), 1…, 1 article). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with C79.00?
Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list C79.00?
A55719 (Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification); A56874 (Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)); A56748 (Billing and Coding: White Cell Colony Stimulating Factors), and 1 more article.
What is ICD-10-CM code C79.00?
C79.00 is the ICD-10-CM code for secondary malignant neoplasm of unspecified kidney and renal pelvis, in category C79 (Secondary malignant neoplasm of other and unspecified sites), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under Q2043
- Watch Q2043 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q2043
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.